Browse a selection of key resources and publications about our pipeline.

CLN-619, a Clinical Stage MICA-B-Specific HIgG1 Monoclonal Antibody, Engages Multiple Immune Effector Cells to Promote Anti-Tumor Activity (2024 AACR)

CD19-Directed T Cell-Engaging Antibodies for the Treatment of Autoimmune Disease (2024 JEM)

CLN-617 is an Intratumorally Injected and Locally Retained Fusion of IL-2 and IL-12 That Drives Systemic Anti-Tumor Activity (2022 SITC)

CLN-617 is a First-in-Class Fusion Protein that Retains IL-2 and IL-12 in Injected Tumors and Potently Triggers Systemic Anti-Tumor Immunity (2023 SITC)

Characterization of the Pharmacodynamic Activity of CLN-619, an Anti-MICA/B Monoclonal Antibody, in Cancer Patients From an Ongoing Phase 1 Trial (2023 SITC)

CLN-978, a Novel CD19/CD3/HSA-Specific T Cell Engager With Extended Serum Half-Life, Is Effective Against Target Cells Expressing Very Low Levels of CD19 (2023 SITC)

CLN-978, a Novel Half-Life Extended CD19/CD3/HSA-Specific T Cell-Engaging Antibody Construct With Potent Activity Against B-Cell Malignancies With Low CD19 Expression (2023 JITC)

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions (2023 JCO)

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients With Advanced Solid Tumors (2023 ASCO)

The Structural Basis for Inhibition of MICA Shedding and Anti-Tumor Activity of the Monoclonal Anti-MICA/B Antibody, CLN-619 (2023 AACR)